Assessing the Safety of Ixekizumab in European Psoriasis Registries (I1F-EW-B008)

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Safety study (incl. comparative)

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  IXEKIZUMAB
• Medical condition to be studied:
  Psoriasis

Population studied

• Age groups:
  Adolescents (12 to < 18 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  2500

Study design details

• Main study objective:
  The objective of this study is to perform safety surveillance by monitoring the incidence of AEs occurring in temporal association with ixekizumab among patients with psoriasis enrolled in European biologic registries.
• Data analysis plan:
  Analysis of BADBIR and PsoBest data is under the control of each registry.